key: cord-0959099-kcm4fqr6
authors: Aponso, Shashendra; Hoou, Loh Chee; Wei, Yeo Yi; Salahuddin, Syed Ahmed; Yit, Pan Jiun
title: Multibacillary leprosy unmasked by COVID-19 vaccination.
date: 2021-11-24
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.11.011
sha: 54f98b63e15590815574251e4d3ca0756d8201e0
doc_id: 959099
cord_uid: kcm4fqr6

nan

Leprosy is a chronic, disfiguring infectious disease. It is traditionally classified into either 34 tuberculoid (paucibacillary) leprosy or lepromatous (multibacillary) leprosy, which differ in 35 the number of bacteria present in the skin and clinical manifestations. Patients in between the 36 two types are classified as borderline. In the context of the COVID-19 pandemic, patients 37 with leprosy will also receive the COVID-19 vaccination. Here we describe a case of 

Immunology of leprosy and diagnostic challenges

Safety and Efficacy of the BNT162b2 mRNA Covid-128

COVID-19 vaccines: modes of immune activation and future 130 challenges

COVID-19 vaccine BNT162b1 elicits human 132 antibody and TH1 T cell responses

Delayed Large Local Reactions to mRNA-1273

Vaccine against SARS-CoV-2

Immune 136 reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker 137 adalimumab in cryptococcal pneumonia

Paradoxical response to 139 antituberculous therapy in infliximab-treated patients with disseminated tuberculosis

Recognizing and managing the immunologic 142 reactions in leprosy

Leprosy -an overview of clinical features, diagnosis, and treatment